Gossamer Bio Inc. (Nasdaq: GOSS), a late-stage clinical biopharmaceutical company, has announced the completion of enrollment for its global registrational Phase 3 PROSERA Study, which is evaluating the drug seralutinib for the treatment of pulmonary arterial hypertension (PAH). The Phase 3 study involves 390 participants and is designed as a double-blind, placebo-controlled trial. The primary endpoint focuses on the change in six-minute walk distance from baseline as compared to placebo at week 24, with key secondary endpoints including time to clinical worsening up to week 48. The study also assesses safety and tolerability. Topline results from the PROSERA Study are anticipated to be announced in February 2026. This follows insights gained from the earlier Phase 2 TORREY Study, with the current patient population closely aligning with the study's objectives.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.